Webster Bank N. A. Increases Stake in Johnson & Johnson (NYSE:JNJ)

Webster Bank N. A. increased its position in Johnson & Johnson (NYSE:JNJ) by 0.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 51,953 shares of the company’s stock after acquiring an additional 285 shares during the quarter. Johnson & Johnson comprises 0.9% of Webster Bank N. A.’s investment portfolio, making the stock its 27th largest holding. Webster Bank N. A.’s holdings in Johnson & Johnson were worth $8,218,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in JNJ. 4J Wealth Management LLC increased its stake in Johnson & Johnson by 2.2% in the 4th quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after buying an additional 62 shares during the period. My Personal CFO LLC increased its stake in Johnson & Johnson by 1.4% in the 4th quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock worth $713,000 after buying an additional 62 shares during the period. Eagle Strategies LLC increased its stake in Johnson & Johnson by 1.8% in the 4th quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after buying an additional 63 shares during the period. Clearview Wealth Advisors LLC increased its stake in Johnson & Johnson by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after buying an additional 64 shares during the period. Finally, Brookmont Capital Management increased its stake in Johnson & Johnson by 0.4% in the 4th quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock worth $2,328,000 after buying an additional 64 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Morgan Stanley cut their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 20th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Up 0.2 %

Shares of Johnson & Johnson stock opened at $146.16 on Friday. The firm’s 50 day moving average price is $148.14 and its 200-day moving average price is $154.06. The company has a market cap of $351.76 billion, a P/E ratio of 9.11, a PEG ratio of 2.43 and a beta of 0.53. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the business earned $2.68 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a $1.24 dividend. The ex-dividend date was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.